- Home
- HIHO vs CVKD Comparison
HIHO vs CVKD Comparison
Compare HIHO & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIHO
- CVKD
- Stock Information
- Founded
- HIHO 1990
- CVKD 2022
- Country
- HIHO Hong Kong
- CVKD United States
- Employees
- HIHO N/A
- CVKD N/A
- Industry
- HIHO Industrial Machinery/Components
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- HIHO Industrials
- CVKD Health Care
- Exchange
- HIHO Nasdaq
- CVKD Nasdaq
- Market Cap
- HIHO 8.2M
- CVKD 17.1M
- IPO Year
- HIHO 1996
- CVKD 2023
- Fundamental
- Price
- HIHO $1.96
- CVKD $15.24
- Analyst Decision
- HIHO
- CVKD Strong Buy
- Analyst Count
- HIHO 0
- CVKD 2
- Target Price
- HIHO N/A
- CVKD $52.50
- AVG Volume (30 Days)
- HIHO 8.5K
- CVKD 59.6K
- Earning Date
- HIHO 10-10-2024
- CVKD 11-08-2024
- Dividend Yield
- HIHO 3.59%
- CVKD N/A
- EPS Growth
- HIHO N/A
- CVKD N/A
- EPS
- HIHO N/A
- CVKD N/A
- Revenue
- HIHO $7,648,000.00
- CVKD N/A
- Revenue This Year
- HIHO N/A
- CVKD N/A
- Revenue Next Year
- HIHO N/A
- CVKD N/A
- P/E Ratio
- HIHO N/A
- CVKD N/A
- Revenue Growth
- HIHO 10.41
- CVKD N/A
- 52 Week Low
- HIHO $1.70
- CVKD $5.40
- 52 Week High
- HIHO $2.36
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- HIHO 59.79
- CVKD 60.90
- Support Level
- HIHO $1.92
- CVKD $11.19
- Resistance Level
- HIHO $2.00
- CVKD $15.93
- Average True Range (ATR)
- HIHO 0.07
- CVKD 1.36
- MACD
- HIHO 0.01
- CVKD 0.23
- Stochastic Oscillator
- HIHO 80.95
- CVKD 61.01
About HIHO Highway Holdings Limited
Highway Holdings Ltd is a holding company. The company is a manufacturer of metal, plastic, electric and electronic components for original equipment manufacturers (OEM) and contract manufacturers. Its operating segment includes Metal stamping and mechanical OEM and Electric OEM. The metal stamping segment focuses on the manufacturing and sale of metal parts and components. The company generates maximum revenue from the Metal stamping and mechanical OEM segment. Geographically, it derives a majority of its revenue from Europe and also has a presence in Hong Kong and China, North America, and Other Asian countries.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.